ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
← catalyst calendarNCT07513285 · readout in 406 d
Sponsored by Acurx Pharmaceuticals Inc. (industry) · ACXP — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-06 | actual | When the study began enrolling |
| Primary completion | 2027-09-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-24 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Clostridium Difficile Infection Recurrence
Intervention
- Drug: Ibezapolstat — also filed as ACX-362E
Primary outcomes
what the primary-completion date above is the date OFEvaluate the rate of CDI Clinical Cure (CC)
measured Day 16
Evaluate the rate of Sustained Clinical Cure (SCC)
measured Day 42
Evaluate the rate of CDI recurrence (rCDI)
measured Day 70
Publications
- PMID 31221610 — cited as background
- PMID 29562266 — cited as background
- PMID 35134880 — cited as background
- PMID 40516571 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ACXP's whole pipeline · Catalyst calendar · Every registered study · What changed